<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01805739</url>
  </required_header>
  <id_info>
    <org_study_id>Multi Modal Cardiac Imaging</org_study_id>
    <nct_id>NCT01805739</nct_id>
  </id_info>
  <brief_title>Multi Modal Cardiac Imaging Prior Transcatheter Aortic Valve Implantation</brief_title>
  <official_title>Multi Modal Cardiac Imaging Prior Transcatheter Aortic Valve Implantation (TAVI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klinik für Kardiologie, Pneumologie und Angiologie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heinrich-Heine University, Duesseldorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transcatheter aortic valve implantation (TAVI) is an emerging alternative therapy for aortic&#xD;
      stenosis for patients ineligible for open heart surgery or at high risk for perioperative&#xD;
      complications. Pre-procedural imaging of the aortic root is essential for selection of the&#xD;
      correct valve prosthesis and to minimize complications as prosthesis mismatch, possibly&#xD;
      subsequent embolization, coronary obstruction, annulus rupture or severe aortic&#xD;
      regurgitation.&#xD;
&#xD;
      The aim of the study is to compare the different imaging modalities for aortic root&#xD;
      measurements.&#xD;
&#xD;
      Aortic root imaging will be performed prior to TAVI-procedure. The contrast injection will be&#xD;
      performed either into the aorta or into the left ventricle. The datasets will be assessed by&#xD;
      blinded-independent observers in a multi-planar reconstruction view.&#xD;
&#xD;
      The study will be performed retrospectively (2009-2012) and prospectively starting 2013.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transcatheter aortic valve implantation (TAVI) is an emerging alternative therapy for aortic&#xD;
      stenosis for patients ineligible for open heart surgery or at high risk for perioperative&#xD;
      complications. Pre-procedural imaging of the aortic root is essential for selection of the&#xD;
      correct valve prosthesis and to minimize complications as prosthesis mismatch, possibly&#xD;
      subsequent embolization, coronary obstruction, annulus rupture or severe aortic&#xD;
      regurgitation.&#xD;
&#xD;
      The aim of the study is to compare the different imaging modalities for aortic root&#xD;
      measurements.&#xD;
&#xD;
      Aortic root imaging will be performed prior to TAVI-procedure. The contrast injection will be&#xD;
      performed either into the aorta or into the left ventricle. The datasets will be assessed by&#xD;
      blinded-independent observers in a multi-planar reconstruction view.&#xD;
&#xD;
      The study will be performed retrospectively (2009-2012) and prospectively starting 2013.&#xD;
&#xD;
      Substudy: &quot;Real-World Experience with Implantation Depth Optimization according to 2020&#xD;
      Recommendations for Evolut R Self-Expanding Transcatheter Aortic Valve: the Düsseldorf Best&#xD;
      Practice Trial.&quot; Aortic valve stenosis treated by transcatheter aortic valve replacement&#xD;
      (TAVR) is one of the most fast-growing sections in interventional cardiology. The Heart&#xD;
      Center Düsseldorf is a high-volume center for treatment of patients suffering of aortic&#xD;
      stenosis treated by TAVR, so we have a great interest in further investigation of process&#xD;
      optimizing and improvement. Therefore, we will focus on optimization of implantation depth&#xD;
      (ID) according to Medtronic®'s best practice recommendations for TAVR deployment in July 2020&#xD;
      regarding new-generation devices Medtronic® CoreValve Evolut. Optimal ID is an important&#xD;
      condition for hemodynamic and clinical outcome due to increased risk of paravalvular leakage&#xD;
      or even valve embolization in implantation that is located too high, whereas deep&#xD;
      implantation is associated with more aortic regurgitation an increased risk of conduction&#xD;
      disturbances associated with higher rates of permanent pacemaker implantation. The aim of&#xD;
      this single-center observational study is to investigate short-term clinical performance,&#xD;
      safety and efficiency outcomes in patients undergoing transfemoral TAVR regarding&#xD;
      Medtronic®'s best practice advices of July 2020 for TAVR deployment with CoreValve Evolut.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2030</completion_date>
  <primary_completion_date type="Anticipated">December 2030</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Assessment of diameters of the aortic annulus using the different imaging modalities</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Implantation depth (ID) measured from NCC in fluoroscopic view</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>left ventricular contrast injection</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of pre-procedural TAVI-imaging for the assessment of the left ventricular outflow tract (LVOT).</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean pressure gradient</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>paravalvular aortic regurgitation</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bleeding and vascular access site complications</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Major Adverse Cardiac Event</measure>
    <time_frame>1 month, 3 months and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Hospitalisation</measure>
    <time_frame>1 month, 3 months and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mortality</measure>
    <time_frame>1 month, 3 months and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>blood samples</measure>
    <time_frame>1 month, 3 months and 12 months</time_frame>
  </other_outcome>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patients with aortic valve stenosis screened for TAVI&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  aortic valve stenosis&#xD;
&#xD;
          -  screened for TAVI&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  unconsciousness, not able to consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malte Kelm, MD</last_name>
    <role>Study Director</role>
    <affiliation>Division of Cardiology, Pulmonary Diseases, Vascular Medicine, University Hospital Duesseldorf</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Malte Kelm, MD</last_name>
    <phone>0049 211 81 18800</phone>
    <email>CTSU@med.uni-duesseldorf.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of Cardiology, Pulmonary Diseases, Vascular Medicine, University Hospital Duesseldorf</name>
      <address>
        <city>Duesseldorf</city>
        <state>NRW</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malte Kelm, MD</last_name>
      <phone>0049 211 81 18800</phone>
      <email>CTSU@med.uni-duesseldorf.de</email>
    </contact>
    <contact_backup>
      <last_name>Rabea Wagstaff, MA</last_name>
      <phone>0049 211 81 18800</phone>
      <email>ctsu@med.uni-duesseldorf.de</email>
    </contact_backup>
    <investigator>
      <last_name>Malte Kelm, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florian Bönner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katharina Hellhammer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tobias Zeus, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ralf Westenfeld, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Verena Veulemans, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kathrin Klein, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Jung, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oliver Maier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shazia Afzal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>March 1, 2013</study_first_submitted>
  <study_first_submitted_qc>March 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2013</study_first_posted>
  <last_update_submitted>October 28, 2020</last_update_submitted>
  <last_update_submitted_qc>October 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Heinrich-Heine University, Duesseldorf</investigator_affiliation>
    <investigator_full_name>Klinik für Kardiologie, Pneumologie und Angiologie</investigator_full_name>
    <investigator_title>Director Division of Cardiology, Pulmonary Diseases, Vascular Medicine</investigator_title>
  </responsible_party>
  <keyword>transcatheter aortic valve implantation</keyword>
  <keyword>CT</keyword>
  <keyword>MRI</keyword>
  <keyword>angiography</keyword>
  <keyword>echocardiography</keyword>
  <keyword>rotational C-arm CT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

